Herjan Coelingh Bennink (HCB), MD, PhD
, trained in Internal Medicine and Gynaecology in Deventer, Leiden and Utrecht, the Netherlands (Dr Pannekoek, Prof Jon van Rood and Prof Ary Haspels) and certified in 1976 as specialist in ObGyn. In 1974 he was Research Fellow at the Center of Reproductive Biology, University of Michigan, Ann Arbor, USA (Prof Jan Behrman). Since 1976 he was director of the Department of Reproductive Endocrinology at the University Hospital in Utrecht. In 1980 he completed his PhD thesis on Gestational Diabetes.
In 1987 HCB joined Organon in the Netherlands as Executive VP of the Women’s Health (WH) R&D programme, where he was responsible for the development of drugs such as recFSH (Puregon) and a GnRH antagonist (Antagon) for IVF, a contraceptive vaginal ring (Nuvaring), a progestin-only implant (Implanon) and a progestin-only pill (Cerazette) for contraception and Tibolone (Livial) for hormone replacement therapy (HRT). From 1997-2005 HCB was visiting professor Reproductive Medicine at the Dutch speaking Free University in Brussels, Belgium (Profs Paul Devroey and André van Steirteghem).
HCB founded Pantarhei Bioscience early 2001 for the development of new drugs for WH applications, such as the natural fetal estrogen Estetrol (E4) for contraception and HRT, a new combined oral contraceptive (COC) preserving sexual function by preventing the loss of testosterone due to COC use (Androgen Restored Contraception) and an immunological method for the treatment of Zona Pellucida 3 (ZP3) antigen expressing ovarian cancer. Late 2014 HCB founded Pantarhei Oncology for the development of drugs for endocrine and reproductive tract cancers such as ZP3 expressing ovarian, prostate and lung cancer and Estetrol for the treatment of breast and prostate cancer.